Head-To-Head Analysis: Onconova Therapeutics (NASDAQ:ONTX) & Ambit Biosciences (AMBI)

Onconova Therapeutics (NASDAQ: ONTX) and Ambit Biosciences (NASDAQ:AMBI) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, risk and dividends.

Profitability

This table compares Onconova Therapeutics and Ambit Biosciences’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Onconova Therapeutics -2,855.94% -558.97% -144.30%
Ambit Biosciences N/A N/A N/A

Insider & Institutional Ownership

25.4% of Onconova Therapeutics shares are held by institutional investors. 27.3% of Onconova Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Onconova Therapeutics and Ambit Biosciences, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Onconova Therapeutics 0 0 4 0 3.00
Ambit Biosciences 0 0 0 0 N/A

Onconova Therapeutics presently has a consensus price target of $7.33, indicating a potential upside of 302.93%.

Earnings and Valuation

This table compares Onconova Therapeutics and Ambit Biosciences’ revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Onconova Therapeutics $5.55 million 3.53 -$19.66 million ($2.77) -0.66
Ambit Biosciences N/A N/A N/A ($1.42) N/A

Ambit Biosciences has lower revenue, but higher earnings than Onconova Therapeutics. Onconova Therapeutics is trading at a lower price-to-earnings ratio than Ambit Biosciences, indicating that it is currently the more affordable of the two stocks.

About Onconova Therapeutics

Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company operates through the identification and development of oncology therapeutics segment. It is focused on discovering and developing small molecule drug candidates to treat cancer. The Company has created a targeted anti-cancer agents designed to work against specific cellular pathways that are important to cancer cells. It has over three clinical-stage product candidates and various preclinical programs that target kinases, cellular metabolism or cell division in preclinical development. The Company’s lead product candidate, rigosertib, is being tested in both intravenous (IV) and oral formulations as a single agent, and the oral formulation is also being tested in combination with azacitidine, in clinical trials for patients with myelodysplastic syndromes (MDS), and related cancers. Its other product candidates include Briciclib and Recilisib.

About Ambit Biosciences

Ambit Biosciences Corporation is a biopharmaceutical company. The Company focused on the discovery, development and commercialization of drugs to treat unmet medical needs in oncology, autoimmune and inflammatory diseases by inhibiting kinases that are important drivers for those diseases. The Company’s lead drug candidate, quizartinib, is in Phase IIb clinical development in patients with relapsed/refractory acute myeloid leukemia (AML). The Company’s second drug candidate in clinical development, AC410, is a potent, selective, orally-administered, small molecule inhibitor of Janus kinase 2 (JAK2) that has potential utility for the treatment of autoimmune and inflammatory diseases. The Company’s third program consists of two selective small molecule compounds, AC708 and AC855, which inhibit the colony-stimulating factor-1 receptor (CSF1R), a receptor tyrosine kinase.

Receive News & Ratings for Onconova Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Onconova Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply